We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable UTI Testing Platform Brings Lab-Quality Molecular Diagnostics to Point-Of-Care Settings

By LabMedica International staff writers
Posted on 25 Apr 2023

Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with 90% of patients being women and the risk increasing with age. More...

UTIs can be painful, debilitating, and potentially lead to severe long-term complications, such as sepsis. However, suitable point-of-care diagnostic tools are lacking, leading to frequent over- and underdiagnosis. UTI treatments account for 10-20% of community antibiotic prescriptions, but many of these antibiotics are prescribed unnecessarily, contributing to the spread of antibiotic resistance. Now, a new point-of-care UTI test can assist clinicians in making evidence-based decisions for UTI patients.

Llusern Scientific (Wales, UK) is launching its UTI assay panel which can test for up to six UTIs at the point-of-care, revolutionizing the way clinicians test for UTIs. The UTI assay panel will test for Escherichia coli (E-coli), Klebsiella spp, Proteus mirabilis, Staphylococcus saprophyticus, Enterococcus spp, and Pseudomonas aeruginosa. This innovative test delivers results in just 40 minutes, avoiding decisions based on ambiguous clinical symptoms or imprecise urine dipstick tests. Clinical results thus far indicate 93% sensitivity and 99% specificity for the test. Additionally, the portable, user-friendly test requires no sample processing, making it adaptable for use in various patient populations and settings, potentially including community and emergency care.

Llusern’s UTI assay panel will run on Lodestar DX, a portable molecular platform designed for UTI and respiratory disease testing that provides lab-accurate results in 30 minutes. This cost-effective technology enables users to perform Loop-mediated isothermal amplification (LAMP) reactions conveniently. The method allows for the amplification and detection of DNA or RNA in a wide array of bacterial and viral targets. Lodestar DX uses an internal algorithm to determine the positivity or negativity of a LAMP reaction, and this algorithm is compatible with numerous LAMP reactions. The system outputs real-time fluorescent reaction data that can be directly captured on a PC and stored for later offline analysis. Capable of running eight reactions simultaneously, Lodestar DX can be operated flexibly based on user requirements. It can be powered by a mains supply using its power adapter or a 15Vdc source like a standard vehicle lighter plug, enabling its use in remote locations.

 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.